Acetylenehexacarbonyldicobalt complexes, a novel class of antitumor drugs

Schmidt, Kathrin; Jung, Manfred; Keilitz, Roland; Schnurr, Beate; Gust, Ronald

doi:10.1016/s0020-1693(00)00139-0

Cited by 92 publications

(90 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, the effects were most marked in human breast cancer cells [24,34,35]. This was also the fact in experiments on human tumour xenografts using a clonogenic assay which has been found to have a high predictive value for further in vivo evaluation [36].…”

Section: Cobalt Compoundsmentioning

confidence: 92%

“…Interestingly, the properties of the alkyne bond are changed towards that of an alkene upon coordination to the hexacarbonyldicobalt cluster. Thus, the angle between the triple bond and the substituents on both sides of the alkyne (X -C=C -X dihedral angle) was found to be significantly lower than 180 degrees, the C - C distance of the triple bond was increased and high signal shifts could be noted in 1 H-and 13 C-NMR spectra [23,24].…”

Section: Cobalt Compoundsmentioning

confidence: 95%

See 1 more Smart Citation

Non Platinum Metal Complexes as Anti‐cancer Drugs

Ott¹,

Gust

2007

Archiv der Pharmazie

Self Cite

545

403

View full text Add to dashboard Cite

The development of metal complexes with platinum central atoms such as cisplatin or carboplatin had an enormous impact on current cancer chemotherapy. However, the spectrum of cancers that can be treated with platinum agents is narrow and treatment efficacy suffers from side effects and resistance phenomena. These unresolved problems in platinum-based anti-cancer therapy have stimulated increased research efforts in the search for novel non platinum-containing metal species as cytostatic agents. Preclinical and clinical investigations showed that the development of new metal agents with modes of action different from cisplatin is possible. Thus, complexes with iron, cobalt, or gold central atoms have shown promising results in preclinical studies and compounds with titanium, ruthenium, or gallium central atoms have already been evaluated in phase I and phase II trials. This review covers some relevant examples of preclinical and clinical research on novel non platinum metal complexes.

show abstract

Section: Cobalt Compoundsmentioning

confidence: 92%

Section: Cobalt Compoundsmentioning

confidence: 95%

Non Platinum Metal Complexes as Anti‐cancer Drugs

Ott¹,

Gust

2007

Archiv der Pharmazie

Self Cite

545

403

View full text Add to dashboard Cite

show abstract

“…[4] Ferrocifen, a ferrocene derivative of the drug tamoxifen shows activity even on hormone-independent cell lines for which tamoxifen is inactive. [5,6] Further examples include {Ru(arene)} complexes, [7] several {Co(CO) 2 (alkyne)} derivatives [8][9][10][11] in addition to the well-studied titanocene dichloride which has been in clinical trials. [12][13][14][15] DNA interaction has been suggested as the mode of action, at least for some of the organometallic antitumor agents.…”

mentioning

confidence: 99%

A Cobaltocenium–Peptide Bioconjugate Shows Enhanced Cellular Uptake and Directed Nuclear Delivery

et al. 2005

View full text Add to dashboard Cite

show abstract

“…[4] Ein Ferrocenderivat des bekannten Wirkstoffs Tamoxifen, Ferrocifen, zeigt eine gute cytostatische Aktivität, selbst bei hormonunabhängigen Zelllinien, die auf Tamoxifen naturgemäß nicht ansprechen. [5,6] Weitere Beispiele sind {Ru(aren)}-Komplexe, [7] verschiedene {Co(CO) 2 -(alkin)}-Derivate [8][9][10][11] und Titanocendichlorid, das bereits in klinischen Studien getestet wurde. [12][13][14][15] Für die meisten dieser Verbindungen ist eine Wechselwirkung mit der DNA als Wirkmechanismus vorgeschlagen worden.…”

unclassified